Abcam, ab258565, Human PARP3 (IRT1) knockout HeLa cell lysate

Size: 1Kit
PARP3 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and Insertion of the selection cassette in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and Insertion of the selection cassette in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PARP3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PARP3/IRT1 also known as Poly(ADP-ribose) polymerase 3 and ADP-ribosyltransferase 1 is a protein involved in DNA repair mechanisms. The protein has a molecular weight of approximately 59 kDa and is expressed in various human tissues predominantly in dividing cells including those in the bone marrow and thymus. PARP3 is one of the members of the PARP family which is known for its role in the base excision repair (BER) of DNA an important process in maintaining genomic stability.
Biological function summary
PARP3 plays a significant role in maintaining chromosomal integrity and facilitating DNA repair. It associates with other proteins as part of the BER complex ensuring efficient repair of DNA single-strand breaks. This protein regulates repair mechanisms by sensing DNA damage and signaling for the recruitment of other DNA repair enzymes. Additionally PARP3 is involved in chromatin remodeling which is critical for accurate DNA repair.
Pathways
PARP3 functions in the DNA damage response (DDR) and the base excision repair pathway. It interacts with other proteins such as XRCC1 an important player in DNA repair to coordinate repair activities. PARP3 modulates the activity of these pathways helping to prevent accumulation of DNA lesions. It plays a part in the signal transduction associated with the cell cycle control which is essential for cellular response to DNA damage and apoptosis.
PARP3 has links to cancer and neurodegenerative diseases. It has been implicated in tumorigenesis due to its role in DNA repair leading to genome stability. Overexpression or mutations might affect the repair process contributing to cancer development. Furthermore PARP3 associates with proteins like p53 a tumor suppressor involved in controlling cell cycle and apoptosis influencing pathways that when altered can lead to neurodegenerative conditions. Understanding PARP3 functions could aid in the development of therapeutic strategies targeting these pathways.